AIM: To investigate the survival impact of common pharmaceuticals, which target stromal interactions, following a pancreaticoduodenectomy for @entity1124 . METHODS: Data was collected retrospectively for 164 @entity1 who underwent a pancreaticoduodenectomy for @entity1124 ( @entity1124 ). Survival analysis was performed on @entity1 receiving the following medications: @entity7774 -converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers ( @entity1605 ), @entity460 channel blockers (CCB), @entity117 , and @entity6817 . Statistical analysis included Kaplan-meier survival estimates and cox multivariate regression; the latter of which allowed for any differences in a range of prognostic indicators between groups. Medications showing a significant survival benefit were investigated in combination with other medications to evaluate synergistic effects. RESULTS: No survival benefit was observed with respect to ACEI/ @entity1605 (n = 41), @entity117 or @entity6817 on individual drug analysis (n = 39). However, the entire CCB group (n = 26) showed a significant survival benefit on multivariate cox regression; hazard ratio (HR) of 0.475 (CI = 0.250-0.902, P = 0.023). Further analysis revealed that this was influenced by a group of @entity1 who were taking @entity117 in combination with CCB; median survival was significantly higher in the CCB + @entity117 group (n = 15) compared with the group taking neither drug (n = 98); 1414 d vs 601 d (P = 0.029, log-rank test). Multivariate cox regression revealed neither @entity117 nor CCB had a statistically significant impact on survival when given alone, however in combination the survival benefit was significant; HR = 0.332 (CI = 0.126-0.870, P = 0.025). None of the other medications showed a survival benefit in any combination. CONCLUSION: @entity117 + CCB in combination appears to increase survival in @entity1 with @entity1124 , highlighting the potential clinical use of combination therapy to target stromal interactions in @entity788 .

Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity1605 :: ('OMIM:217000', 'Disease') :: ['ARB'] @entity1124 :: ('MESH:D021441', 'Disease') :: ['PDAC', 'pancreatic ductal adenocarcinoma'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['angiotensin'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity6817 :: ('D019821', 'Chemical') :: ['statins']
@entity1124 :: (MESH:D021441,Disease) :: ['pancreatic ductal adenocarcinoma']
